© 2003 by Oxford University Press
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2003 Oxford University Press
ARTICLE |
Role of Thymosin 
4 in Tumor Metastasis and Angiogenesis
Affiliations of authors: Craniofacial Developmental Biology and Regeneration Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD (HJC, HKK); Department of Oral Histology, College of Dentistry, Chosun University, Gwanju, Korea (MJJ).
Correspondence to: Hynda K. Kleinman, PhD, Craniofacial Developmental Biology and Regeneration Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD 20892 (e-mail: hkleinman{at}dir.nidcr.nih.gov)
Background: Expression of the small peptide thymosin 
4 is associated with angiogenesis induction, accelerated wound healing, and the metastatic potential of tumor cells. However, little is known about the mechanism(s) by which thymosin 4 promotes metastasis. Methods: Northern blot analysis and immunohistochemistry were used to examine thymosin 4 expression in mouse melanoma B16 cell lines and in B16-F10 cells derived from metastatic mouse lung tumors, respectively. B16-F10 cells infected with adenoviruses containing a thymosin 4 expression vector or an empty vector were injected subcutaneously and intravenously into C57BL/6 mice to evaluate tumor growth and metastatic potential, respectively. In vitro assays were used to study cell migration, invasion, matrix metalloproteinase activity, cell proliferation, and angiogenic activity of adenovirus-infected B16-F10 cells. Statistical significance of all results was analyzed by two-tailed Student’s t tests. Results: Thymosin 4 mRNA was expressed in primary cultured B16-F10 cells derived from lung metastases and in B16-F10 cells that had formed lung tumors after being injected into mice but not in the B16-F1, B16-F10, or B16-BL6 cell lines. The mean tumor sizes in mice 20 days after injection with B16-F10 cells infected with thymosin 4–expressing adenovirus and with control adenovirus were 21.7 mm (95% confidence interval [CI] = 17.7 to 25.7 mm) and 13.3 mm (95% CI = 11.1 to 15.3 mm), respectively (difference = 8.4 mm; P = .036). The mean numbers of metastatic lung nodules in mice (n = 20) 2 weeks after intravenous injection with thymosin 4–expressing adenovirus and with control adenovirus were 46.7 (95% CI = 35.0 to 57.7) and 10.9 (95% CI = 6.2 to 15.6), respectively (difference = 35.8 metastatic lung nodules, P<.001). Thymosin 4 overexpression was associated with a mean 2.3-fold increase (95% CI = 1.9- to 2.7-fold increase; P<.001) in B16-F10 cell migration and a mean 4.4-fold increase (95% CI = 3.3- to 5.5-fold increase; P<.001) in the number of blood vessels in solid tumors derived from injected B16-F10 cells but had no effect on cell invasion, proliferation, or matrix metalloproteinase activity. This induction of angiogenesis by thymosin 4 was associated with induction of vascular endothelial growth factor expression. Conclusion: Thymosin 4 may stimulate tumor metastasis by activating cell migration and angiogenesis.
CiteULike 
Connotea 
Del.icio.us What's this?
Editorial about this Article
-
Thymosin 4: A New Molecular Target for Antitumor Strategies
- Allan L. Goldstein
J Natl Cancer Inst 2003 95: 1646-1647.[Extract] [Full Text] [PDF]
This article has been cited by other articles:
|
|
 |
|
  T. Plavina, M. Hincapie, E. Wakshull, M. Subramanyam, and W. S. Hancock Increased Plasma Concentrations of Cytoskeletal and Ca2+-Binding Proteins and Their Peptides in Psoriasis Patients Clin. Chem., November 1, 2008; 54(11): 1805 - 1814. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Iguchi, M. Ito, S. Usui, A. Mizokami, M. Namiki, and K. Hirano Downregulation of Thymosin {beta}4 Expression by Androgen in Prostate Cancer LNCaP Cells J Androl, March 1, 2008; 29(2): 207 - 212. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Bednarek, J. Boncela, K. Smolarczyk, A. Cierniewska-Cieslak, E. Wyroba, and C. S. Cierniewski Ku80 as a Novel Receptor for Thymosin 4 That Mediates Its Intracellular Activity Different from G-actin Sequestering J. Biol. Chem., January 18, 2008; 283(3): 1534 - 1544. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Was, T. Cichon, R. Smolarczyk, D. Rudnicka, M. Stopa, C. Chevalier, J. J. Leger, B. Lackowska, A. Grochot, K. Bojkowska, et al. Overexpression of Heme Oxygenase-1 in Murine Melanoma: Increased Proliferation and Viability of Tumor Cells, Decreased Survival of Mice Am. J. Pathol., December 1, 2006; 169(6): 2181 - 2198. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Ding, A. Lambrechts, M. Parepally, and P. Roy Silencing profilin-1 inhibits endothelial cell proliferation, migration and cord morphogenesis J. Cell Sci., October 1, 2006; 119(19): 4127 - 4137. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Tang, D. L. Dai, M. Su, M. Martinka, G. Li, and Y. Zhou Aberrant Expression of Collagen Triple Helix Repeat Containing 1 in Human Solid Cancers. Clin. Cancer Res., June 15, 2006; 12(12): 3716 - 3722. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-L. Hsiao, W.-S. Wang, P.-M. Chen, and Y. Su Overexpression of thymosin {beta}-4 renders SW480 colon carcinoma cells more resistant to apoptosis triggered by FasL and two topoisomerase II inhibitors via downregulating Fas and upregulating Survivin expression, respectively Carcinogenesis, May 1, 2006; 27(5): 936 - 944. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Nummela, M. Yin, M. Kielosto, V. Leaner, M. J. Birrer, and E. Holtta Thymosin {beta}4 Is a Determinant of the Transformed Phenotype and Invasiveness of S-Adenosylmethionine Decarboxylase-Transfected Fibroblasts Cancer Res., January 15, 2006; 66(2): 701 - 712. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Reyzer, R. L. Caldwell, T. C. Dugger, J. T. Forbes, C. A. Ritter, M. Guix, C. L. Arteaga, and R. M. Caprioli Early Changes in Protein Expression Detected by Mass Spectrometry Predict Tumor Response to Molecular Therapeutics Cancer Res., December 15, 2004; 64(24): 9093 - 9100. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G Eisenhofer, T-T Huynh, K Pacak, F M Brouwers, M M Walther, W M Linehan, P J Munson, M Mannelli, D S Goldstein, and A G Elkahloun Distinct gene expression profiles in norepinephrine- and epinephrine-producing hereditary and sporadic pheochromocytomas: activation of hypoxia-driven angiogenic pathways in von Hippel-Lindau syndrome Endocr. Relat. Cancer, December 1, 2004; 11(4): 897 - 911. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. K. Jain, S. M. Moore, K. Yamaguchi, T. E. Eling, and S. J. Baek Selective Nonsteroidal Anti-Inflammatory Drugs Induce Thymosin {beta}-4 and Alter Actin Cytoskeletal Organization in Human Colorectal Cancer Cells J. Pharmacol. Exp. Ther., December 1, 2004; 311(3): 885 - 891. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Wang, O. A. Carretero, X.-Y. Yang, N.-E. Rhaleb, Y.-H. Liu, T.-D. Liao, and X.-P. Yang N-acetyl-seryl-aspartyl-lysyl-proline stimulates angiogenesis in vitro and in vivo Am J Physiol Heart Circ Physiol, November 1, 2004; 287(5): H2099 - H2105. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. L. Goldstein Thymosin {beta}4: A New Molecular Target for Antitumor Strategies J Natl Cancer Inst, November 19, 2003; 95(22): 1646 - 1647. [Full Text] [PDF]
|
|